4,757 Shares in TransMedics Group, Inc. (NASDAQ:TMDX) Purchased by Claro Advisors LLC

Claro Advisors LLC acquired a new position in TransMedics Group, Inc. (NASDAQ:TMDX) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 4,757 shares of the company’s stock, valued at approximately $297,000.

A number of other hedge funds have also added to or reduced their stakes in TMDX. Driehaus Capital Management LLC grew its holdings in TransMedics Group by 15.8% during the 2nd quarter. Driehaus Capital Management LLC now owns 1,486,073 shares of the company’s stock valued at $223,832,000 after buying an additional 202,867 shares in the last quarter. Principal Financial Group Inc. grew its holdings in TransMedics Group by 260.1% during the 3rd quarter. Principal Financial Group Inc. now owns 202,287 shares of the company’s stock valued at $31,759,000 after buying an additional 146,115 shares in the last quarter. Hood River Capital Management LLC purchased a new position in TransMedics Group during the 2nd quarter valued at about $18,854,000. Canada Pension Plan Investment Board purchased a new position in TransMedics Group during the 2nd quarter valued at about $16,086,000. Finally, Public Sector Pension Investment Board purchased a new position in TransMedics Group during the 3rd quarter valued at about $11,079,000. Hedge funds and other institutional investors own 99.67% of the company’s stock.

TransMedics Group Stock Performance

NASDAQ:TMDX opened at $62.54 on Wednesday. The business has a 50 day moving average of $73.15 and a 200 day moving average of $119.58. The company has a market capitalization of $2.10 billion, a price-to-earnings ratio of 66.53 and a beta of 2.12. TransMedics Group, Inc. has a 1-year low of $58.27 and a 1-year high of $177.37. The company has a debt-to-equity ratio of 2.42, a current ratio of 8.20 and a quick ratio of 7.33.

TransMedics Group (NASDAQ:TMDX) last released its earnings results on Monday, October 28th. The company reported $0.12 earnings per share for the quarter, missing analysts’ consensus estimates of $0.29 by ($0.17). The firm had revenue of $108.76 million during the quarter, compared to the consensus estimate of $115.00 million. TransMedics Group had a return on equity of 18.74% and a net margin of 8.14%. The business’s quarterly revenue was up 63.7% compared to the same quarter last year. During the same quarter in the previous year, the firm earned ($0.12) EPS. On average, sell-side analysts predict that TransMedics Group, Inc. will post 1 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of research analysts have weighed in on TMDX shares. Needham & Company LLC reaffirmed a “hold” rating on shares of TransMedics Group in a report on Wednesday, December 11th. Robert W. Baird reduced their target price on TransMedics Group from $150.00 to $120.00 and set an “outperform” rating for the company in a report on Wednesday, December 11th. Canaccord Genuity Group dropped their price target on TransMedics Group from $109.00 to $104.00 and set a “buy” rating for the company in a research report on Wednesday, November 20th. TD Cowen dropped their price target on TransMedics Group from $175.00 to $120.00 and set a “buy” rating for the company in a research report on Monday, November 18th. Finally, JPMorgan Chase & Co. reiterated a “neutral” rating and set a $75.00 price target (down previously from $116.00) on shares of TransMedics Group in a research report on Tuesday, December 17th. Three equities research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $122.70.

Insider Buying and Selling

In related news, insider Tamer I. Khayal sold 1,084 shares of the business’s stock in a transaction that occurred on Monday, December 2nd. The stock was sold at an average price of $86.40, for a total value of $93,657.60. Following the completion of the sale, the insider now owns 20,843 shares in the company, valued at $1,800,835.20. The trade was a 4.94 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Edward M. Basile sold 6,750 shares of the business’s stock in a transaction that occurred on Tuesday, November 5th. The stock was sold at an average price of $83.55, for a total value of $563,962.50. Following the completion of the sale, the director now owns 732 shares of the company’s stock, valued at $61,158.60. The trade was a 90.22 % decrease in their position. The disclosure for this sale can be found here. 7.00% of the stock is currently owned by corporate insiders.

About TransMedics Group

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.